<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0121-5256</journal-id>
<journal-title><![CDATA[Revista Med]]></journal-title>
<abbrev-journal-title><![CDATA[rev.fac.med]]></abbrev-journal-title>
<issn>0121-5256</issn>
<publisher>
<publisher-name><![CDATA[Universidad Militar Nueva Granada. Facultad de Medicina]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0121-52562012000200005</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[ESTADO DEL ARTE: TUMORES DE CRESTA NEURAL, NEUROBLASTOMA FISIOPATOLOGÍA, DIAGNÓSTICO Y TRATAMIENTO]]></article-title>
<article-title xml:lang="en"><![CDATA[STATE OF ART: NEURAL CREST TUMORS, NEUROBLASTOMA (NB) PATHOPHYSIOLOGY, DIAGNOSIS AND TREATMENT]]></article-title>
<article-title xml:lang="pt"><![CDATA[ESTADO DE ARTE: TUMORES DE CRESTA NEURAL, NEUROBLASTOMA FISIOPATOLOGIA, DIAGNÓSTICO E TRATAMENTO]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[ÁLVAREZ]]></surname>
<given-names><![CDATA[ANDRÉS M.]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[LAMARRE]]></surname>
<given-names><![CDATA[REYNALD]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Cleveland Clinic Research Fellow Orthopaedic and Neurological Surgery Department ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2012</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2012</year>
</pub-date>
<volume>20</volume>
<numero>2</numero>
<fpage>38</fpage>
<lpage>49</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_arttext&amp;pid=S0121-52562012000200005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_abstract&amp;pid=S0121-52562012000200005&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.co/scielo.php?script=sci_pdf&amp;pid=S0121-52562012000200005&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[El neuroblastoma es el tumor sólido extracraneal más frecuente en la infancia, con incidencia de 650 casos al año en los Estados Unidos de America y 100 casos por año en Italia y España. Se trata de un tumor que evoluciona de forma variable, desde la regresión espontánea hasta un comportamiento muy maligno, sobre todo en niños en edades mayores y con la existencia de enfermedad diseminada. Los signos y síntomas de presentación del neuroblastoma reflejan la localización del tumor y debido a las múltiples presentaciones clínicas, puede confundirse con gran variedad de patologías. Su tratamiento incluye la cirugía, la quimioterapia, la radioterapia y la terapia inmunológica. El papel de cada uno se determina anticipando el comportamiento clínico del tumor en cada caso, considerando la edad, el estadio y determinados parámetros biológicos. En los últimos 10 años, la estratificación por grupos de riesgo de los pacientes con neuroblastoma, basada en el análisis de un panel amplio de variables clínicas y biológicas, entre las que destacan la edad, el estadio y la amplificación del N-MYC, ha permitido un diagnóstico temprano y nuevas pautas para una mejoría importante en su tratamiento. El tratamiento del neuroblastoma se diseña hoy en día según grupos de riesgo, que se definen por parámetros clínicos y biológicos cada vez más sofisticados. El mejor conocimiento de la biología del neuroblastoma ha permitido distinguir entre aquellos tumores que pueden curarse con un tratamiento mínimo y los que requieren de un tratamiento multidisciplinario y complejo para tener posibilidades de curación. Es fundamental realizar al diagnóstico temprano con indicaciones de estadio y desarrollo de una terapia oportuna.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Neuroblastoma (NB) is the most common extracranial solid cancer in childhood and the most common cancer in infancy, with an annual incidence of about 650 cases per year in the US, and 100 cases per year in Italy and Spain. Roughly 50 percent of neuroblastoma cases occur in children younger than two years of age. It is a neuroendocrine tumor, arising from neural crest cells of the sympathetic nervous system (SNS). It most frequently originates in one of the adrenal glands, but can also develop in nerve tissues located in the neck, chest, abdomen, and pelvis. It is a highly variable tumor that can spontaneously regress or have highly malignant behavior, especially in older children with disseminated disease. Signs and symptoms of neuroblastoma reflect the presentation of tumor location and because of the multiple clinical presentations, can be confused with a variety of pathologies. Treatment modalities include surgery, chemotherapy, radiotherapy and immunotherapy. The role of each method is determined in advance of the clinical behavior of the tumor on a case specific basis, consideration of the age, stage and biological parameters. Over the past decade, stratification of patients with risk factors for neuroblastoma based on the analysis of a large panel of clinical and biological variables, among which are age, stage and N-MYC amplification, has allowed for early diagnosis and the generation of new guidelines for major advancements in treatment. Today, treatment of neuroblastoma has become increasingly sophisticated and is influenced by risk factors as well as clinical and biological parameters. A better understanding of the biology of neuroblastoma has allowed for the differentiation between tumors that can be cured with minimal treatment and those requiring a multidisciplinary and complex approach in order to have a chance of cure. Early diagnosis with staging is essential in the development of an appropriate therapy.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[O neuroblastoma é o tumor sólido extra-craneal mais frequente na infância, com incidência de 650 casos por ano nos Estados Unidos da América e 100 casos por ano na Itália e Espanha. Trata-se de um tumor que evolui de forma variável, desde a regressão espontânea até um comportamento muito maligno, sobretudo em crianças com idades maiores e com a existência de doença disseminada. Os sinais e sintomas de apresentação do neuroblastoma refletem a localização do tumor e devido as múltiplas apresentações clínicas, pode ser confundido com uma grande variedade de patologias. Seu tratamento inclui a cirurgia, a quimioterapia, a radioterapia e a terapia imunológica. O papel de cada um é determinado antecipando o comportamento clínico do tumor em cada caso, considerando a idade, o estádio e determinados parâmetros biológicos. Nos últimos 10 anos, a estratificação por grupos de risco dos pacientes com neuroblastoma, baseada na análise de um painel amplo de variáveis clínicas e biológicas, entre as que destacam a idade, o estádio, e a amplificação do N-MYC, permitem um diagnostico precoce e novas pautas para uma melhoria importante no seu tratamento. O tratamento do neuroblastoma é feito hoje em dia de acordo com grupos de risco, que são definidos por parâmetros clínicos e biológicos cada vez mais sofisticados. O melhor conhecimento da biologia do neuroblastoma permitiu distinguir entre os tumores que podem ser curados com um tratamento mínimo e os que requerem um tratamento multidisciplinar e complexo para ter possibilidades de cura. É fundamental realizar o diagnóstico precoce com indicações de estádio e desenvolvimento de uma terapia oportuna.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Neuroblastoma]]></kwd>
<kwd lng="es"><![CDATA[cresta neural]]></kwd>
<kwd lng="es"><![CDATA[tumor cerebral]]></kwd>
<kwd lng="es"><![CDATA[infancia]]></kwd>
<kwd lng="es"><![CDATA[N-MYC]]></kwd>
<kwd lng="es"><![CDATA[médula]]></kwd>
<kwd lng="es"><![CDATA[síndrome de Homer]]></kwd>
<kwd lng="es"><![CDATA[NCMAM]]></kwd>
<kwd lng="en"><![CDATA[Neuroblastoma]]></kwd>
<kwd lng="en"><![CDATA[neural crest]]></kwd>
<kwd lng="en"><![CDATA[brain tumor]]></kwd>
<kwd lng="en"><![CDATA[childhood]]></kwd>
<kwd lng="en"><![CDATA[N-MYC]]></kwd>
<kwd lng="en"><![CDATA[bone]]></kwd>
<kwd lng="en"><![CDATA[Homer syndrome]]></kwd>
<kwd lng="en"><![CDATA[NCMAM]]></kwd>
<kwd lng="pt"><![CDATA[Neuroblastoma]]></kwd>
<kwd lng="pt"><![CDATA[cresta neural]]></kwd>
<kwd lng="pt"><![CDATA[tumor cerebral]]></kwd>
<kwd lng="pt"><![CDATA[infância]]></kwd>
<kwd lng="pt"><![CDATA[N-MYC]]></kwd>
<kwd lng="pt"><![CDATA[medula]]></kwd>
<kwd lng="pt"><![CDATA[síndrome de Homer]]></kwd>
<kwd lng="pt"><![CDATA[NCMAM]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[  ]]></body><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carrasquillo]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Pandit-Taskar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Radionuclide therapy of adrenal tumors]]></article-title>
<source><![CDATA[J Surg Oncol]]></source>
<year>2012</year>
<month> J</month>
<day>un</day>
<volume>20</volume>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Asgharzadeh]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pique-Regi]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Sposto]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification]]></article-title>
<source><![CDATA[J Natl Cancer Inst]]></source>
<year>2006</year>
<volume>98</volume>
<page-range>1193-203</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pardal]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Clarke]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Morrison]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Applying the principles of stem-cell biology to cancer]]></article-title>
<source><![CDATA[Nat Rev Cancer]]></source>
<year>2003</year>
<volume>3</volume>
<page-range>895-902</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vescovi]]></surname>
<given-names><![CDATA[AL]]></given-names>
</name>
<name>
<surname><![CDATA[Galli]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Reynolds]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Brain tumour stem cells]]></article-title>
<source><![CDATA[Nat Rev Cancer]]></source>
<year>2006</year>
<volume>6</volume>
<page-range>425-36</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bown]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Neuroblastoma tumour genetics: Clinical and biological aspects]]></article-title>
<source><![CDATA[JClin Pathol]]></source>
<year>2001</year>
<volume>54</volume>
<page-range>897-910</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brodeur]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Neuroblastoma: biological insights into a clinical enigma]]></article-title>
<source><![CDATA[Nature Reviews/cancer]]></source>
<year>2003</year>
<volume>3</volume>
<page-range>203-16</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brodeur]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Maris]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Neuroblastoma]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Pizzo]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Poplack]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
</person-group>
<source><![CDATA[Principles and Practice of Pediatric Oncology]]></source>
<year>2001</year>
<edition>4ª</edition>
<publisher-loc><![CDATA[Philadelphia ]]></publisher-loc>
<publisher-name><![CDATA[Lippincott Williams & Wilkins]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[López-Ibor]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Tumores de cresta neural: Hematología y oncología ediátricas]]></source>
<year>2006</year>
<publisher-loc><![CDATA[Madrid ]]></publisher-loc>
<publisher-name><![CDATA[Ergon]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simon]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hero]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Benz-Bohm]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Von Schweinitz]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Berthold]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Review of image defined risk factors in localized neuroblastoma patients: Results of the GPOH NB97 Trial]]></article-title>
<source><![CDATA[Pediatr Blood Câncer]]></source>
<year>2008</year>
<volume>50</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>965-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paramasivam]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sambantham]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Shabnam]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Anti-cancer effects of thymoquinone in mouse neuroblastoma (Neuro-2a) cells through caspase-3 activation with down-regulation of XIAP]]></article-title>
<source><![CDATA[Toxicol Lett]]></source>
<year>2012</year>
<month> J</month>
<day>un</day>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Yoo]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hypervascular hepatic nodules in childhood cancer survivors: clinical and imaging features]]></article-title>
<source><![CDATA[Clin Imaging]]></source>
<year>2012</year>
<month> J</month>
<day>ul</day>
<volume>36</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>301-7</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zwaveling]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Tytgat]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[van der Zee]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Is complete surgical resection of stage 4 neuroblastoma a prerequisite for optimal survival or may >95 % tumour resection suffice?]]></article-title>
<source><![CDATA[Pediatr Surg Int]]></source>
<year>2012</year>
<month> J</month>
<day>un</day>
</nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grosfeld]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Risk-based management of solid tumors in children]]></article-title>
<source><![CDATA[Am J Surg]]></source>
<year>2000</year>
<month> N</month>
<day>ov</day>
<volume>180</volume>
<page-range>322-7</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berthold]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Hero]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Neuroblastoma: current drug therapy recommendations as part of the total treatment approach]]></article-title>
<source><![CDATA[Drugs]]></source>
<year>2000</year>
<month> J</month>
<day>un</day>
<volume>59</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1261-77</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheung]]></surname>
<given-names><![CDATA[NV]]></given-names>
</name>
<name>
<surname><![CDATA[Kushner]]></surname>
<given-names><![CDATA[BH]]></given-names>
</name>
<name>
<surname><![CDATA[Kramer]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Monoclonal antibodybased therapy of neuroblastoma]]></article-title>
<source><![CDATA[Hematol Oncol Clin North Am]]></source>
<year>2001</year>
<month> O</month>
<day>ct</day>
<volume>15</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>853-66</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Matthay]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Villablanca]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Seeger]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Stram]]></surname>
<given-names><![CDATA[DO]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Ramsay]]></surname>
<given-names><![CDATA[NK]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1999</year>
<month> O</month>
<day>ct</day>
<volume>341</volume>
<numero>16</numero>
<issue>16</issue>
<page-range>1165-73</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hoefnagel]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Nuclear Medicine Therapy of Neuroblastoma]]></article-title>
<source><![CDATA[Q J Nucl Med]]></source>
<year>1999</year>
<month> D</month>
<day>ec</day>
<volume>43</volume>
<page-range>336-43</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[D'Angio]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sather]]></surname>
<given-names><![CDATA[HN]]></given-names>
</name>
<name>
<surname><![CDATA[de Lorimer]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Dalton]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ungerleider]]></surname>
<given-names><![CDATA[RS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A comparison of four staging systems for localized and regional neuroblastoma: a report from the children's cancer study group]]></article-title>
<source><![CDATA[J Clin Onc]]></source>
<year>1990</year>
<month> A</month>
<day>pr</day>
<volume>8</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>678-688</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Partrick]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Bensar]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Geiger]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Teitelbaum]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Successful throacoscopic lung biopsy in children utilizing preoperative CT-guided localization]]></article-title>
<source><![CDATA[J Pediatr Surg]]></source>
<year>2002</year>
<volume>37</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>970-973</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Geiger]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Hutchinson]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hohenkirk]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[McKenna]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Yanik]]></surname>
<given-names><![CDATA[GA]]></given-names>
</name>
<name>
<surname><![CDATA[Levine]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Vvaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific t cells and mediate tumor regression]]></article-title>
<source><![CDATA[Cancer Research]]></source>
<year>2001</year>
<volume>61</volume>
<page-range>8513-8519</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hemmila]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
<name>
<surname><![CDATA[Foley]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Castle]]></surname>
<given-names><![CDATA[VP]]></given-names>
</name>
<name>
<surname><![CDATA[Hirschl]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The response to splenectomy in pediatric patients with ideopathic thrombocytopenic purpura who fail high-dose intravenous immune globulin]]></article-title>
<source><![CDATA[J Ped Surg]]></source>
<year>2000</year>
<volume>35</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>967-72</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Azizkhan]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
<name>
<surname><![CDATA[Rescorla]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Haase]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Applebaum]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Dillon]]></surname>
<given-names><![CDATA[PW]]></given-names>
</name>
<name>
<surname><![CDATA[Coran]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Diagnosis, management and outcome of teratomas in neonates and infants: a multi-institutional study]]></article-title>
<source><![CDATA[Paediatr Croat]]></source>
<year>1999</year>
<volume>43</volume>
<page-range>163-171</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barnhart]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Hirschl]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Garver]]></surname>
<given-names><![CDATA[KA]]></given-names>
</name>
<name>
<surname><![CDATA[Geiger]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Harmon]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Coran]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Conservative management of mesenchymal hamartoma of the liver]]></article-title>
<source><![CDATA[J Ped Surg]]></source>
<year>1997</year>
<volume>32</volume>
<page-range>1495-1498</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Geiger]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Surgery for hepatoblastoma in children]]></article-title>
<source><![CDATA[current opinion in pediatrics]]></source>
<year>1996</year>
<volume>8</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>282-290</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dillion]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Whalen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Azizkhan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Haase]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Coran]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
<name>
<surname><![CDATA[King]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Neonatal soft tissue sarcomas: The influence of pathology on treatment and survival]]></article-title>
<source><![CDATA[J Ped Surg]]></source>
<year>1995</year>
<volume>30</volume>
<page-range>1038-1041</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Geiger]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
<name>
<surname><![CDATA[Hutchinson]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hohenkirk]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[McKenna]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mul]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Treatment of solid tumours in children with tumour lysate-pulsed dendritic cells]]></article-title>
<source><![CDATA[The Lancet]]></source>
<year>2000</year>
<volume>356</volume>
<numero>9236</numero>
<issue>9236</issue>
<page-range>1163-1164</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schmeling]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Coran]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Wilms' Tumor (Nephroblastoma)]]></article-title>
<source><![CDATA[Pediatric Rounds]]></source>
<year>1988</year>
<numero>8</numero>
<issue>8</issue>
<page-range>3-5</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[D'Angio]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
<name>
<surname><![CDATA[Randolph]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[A proposed staging for children with neuroblastoma: Children's Cancer Study Group A]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>1971</year>
<volume>27</volume>
<page-range>374-378</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilson]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Draper]]></surname>
<given-names><![CDATA[GJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Neuroblastoma, its natural history and prognosis: A study of 487 cases]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>1974</year>
<volume>3</volume>
<page-range>301-307</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shimada]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Chatten]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Newton]]></surname>
<given-names><![CDATA[WA Jr]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Histopathologic prognostic factors in neuroblastic tumors: Definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas]]></article-title>
<source><![CDATA[J Natl Cancer Inst]]></source>
<year>1984</year>
<volume>73</volume>
<page-range>405-416</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brodeur]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Seeger]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Schwab]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage]]></article-title>
<source><![CDATA[Science]]></source>
<year>1984</year>
<volume>224</volume>
<page-range>1121-1124</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seeger]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Brodeur]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Sather]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1985</year>
<volume>313</volume>
<page-range>1111-1116</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kushner]]></surname>
<given-names><![CDATA[BH]]></given-names>
</name>
<name>
<surname><![CDATA[Cheung]]></surname>
<given-names><![CDATA[NK]]></given-names>
</name>
<name>
<surname><![CDATA[LaQuaglia]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[International neuroblastoma staging system stage 1 neuroblastoma: A prospective study and literature review]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>1996</year>
<volume>14</volume>
<page-range>2174-2180</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nitschke]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[EI]]></given-names>
</name>
<name>
<surname><![CDATA[Shochat]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Localized neuroblastoma treated by surgery: A Pediatric Oncology Group study]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>1988</year>
<volume>6</volume>
<page-range>1271-1279</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alvarado]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[London]]></surname>
<given-names><![CDATA[WB]]></given-names>
</name>
<name>
<surname><![CDATA[Look]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Natural history and biology of stage A neuroblastoma: A Pediatric Oncology Group study]]></article-title>
<source><![CDATA[J Pediatr Hematol Oncol]]></source>
<year>2000</year>
<volume>22</volume>
<page-range>197-205</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Perez]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Matthay]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Atkinson]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: A Children's Cancer Group study]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2000</year>
<volume>18</volume>
<page-range>18-26</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Matthay]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Villablanca]]></surname>
<given-names><![CDATA[JG]]></given-names>
</name>
<name>
<surname><![CDATA[Seeger]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Treatment of highrisk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid: Children's Cancer Group]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1999</year>
<volume>341</volume>
<page-range>1165-1173</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bowman]]></surname>
<given-names><![CDATA[LC]]></given-names>
</name>
<name>
<surname><![CDATA[Castleberry]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Cantor]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Genetic staging of unresectable or metastatic neuroblastoma in infants: A Pediatric Oncology Group study]]></article-title>
<source><![CDATA[J Natl Cancer Inst]]></source>
<year>1997</year>
<volume>89</volume>
<page-range>373-380</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Lukens]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
<name>
<surname><![CDATA[Seeger]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2000</year>
<volume>18</volume>
<page-range>1260-1268</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schwab]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Alitalo]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Klempnauer]]></surname>
<given-names><![CDATA[KH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour]]></article-title>
<source><![CDATA[Nature]]></source>
<year>1983</year>
<volume>305</volume>
<page-range>245-248</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shapiro]]></surname>
<given-names><![CDATA[DN]]></given-names>
</name>
<name>
<surname><![CDATA[Valentine]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Rowe]]></surname>
<given-names><![CDATA[ST]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Detection of N-myc gene amplification by fluorescence in situ hybridization: Diagnostic utility for neuroblastoma]]></article-title>
<source><![CDATA[American J Pathol]]></source>
<year>1993</year>
<volume>142</volume>
<page-range>1339-1346</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Look]]></surname>
<given-names><![CDATA[AT]]></given-names>
</name>
<name>
<surname><![CDATA[Hayes]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
<name>
<surname><![CDATA[Nitschke]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cellular DNA content as a predictor of response to chemotherapy in infants with unresectable neuroblastoma]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1984</year>
<volume>311</volume>
<page-range>231-235</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brodeur]]></surname>
<given-names><![CDATA[GM]]></given-names>
</name>
<name>
<surname><![CDATA[Pritchard]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Berthold]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>1993</year>
<volume>11</volume>
<page-range>1466-1477</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kaplan]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Meier]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Nonparametric estimation from incomplete observations]]></article-title>
<source><![CDATA[J Am Stat Assoc]]></source>
<year>1958</year>
<volume>53</volume>
<page-range>457-481</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Matthay]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Perez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Seeger]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Successful treatment of stage III neuroblastoma based on prospective biologic staging: A Children's Cancer Group study]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>1998</year>
<volume>16</volume>
<page-range>1256-1264</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kushner]]></surname>
<given-names><![CDATA[BH]]></given-names>
</name>
<name>
<surname><![CDATA[Cheung]]></surname>
<given-names><![CDATA[NK]]></given-names>
</name>
<name>
<surname><![CDATA[LaQuaglia]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>1996</year>
<volume>14</volume>
<page-range>373-381</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cheung]]></surname>
<given-names><![CDATA[NK]]></given-names>
</name>
<name>
<surname><![CDATA[Kushner]]></surname>
<given-names><![CDATA[BH]]></given-names>
</name>
<name>
<surname><![CDATA[LaQuaglia]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Survival from non-stage 4 neuroblastoma without cytotoxic therapy: An analysis of clinical and biological markers]]></article-title>
<source><![CDATA[Eur J Cancer]]></source>
<year>1997</year>
<volume>33</volume>
<page-range>2117-2120</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kushner]]></surname>
<given-names><![CDATA[BH]]></given-names>
</name>
<name>
<surname><![CDATA[Kramer]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[LaQuaglia]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Curability of recurrent disseminated disease after surgery alone for local-regional neuroblastoma using intensive chemotherapy and anti-G(D2) immunotherapy]]></article-title>
<source><![CDATA[J Pediatr Hematol Oncol]]></source>
<year>2003</year>
<volume>25</volume>
<page-range>515-519</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[AE]]></given-names>
</name>
<name>
<surname><![CDATA[Silber]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Shpilsky]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Successful management of low-stage neuroblastoma without adjuvant therapies: A comparison of two decades, 1972 through 1981 and 1982 through 1992, in a single institution]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>1996</year>
<volume>14</volume>
<page-range>2504-2510</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Matthay]]></surname>
<given-names><![CDATA[KK]]></given-names>
</name>
<name>
<surname><![CDATA[Sather]]></surname>
<given-names><![CDATA[HN]]></given-names>
</name>
<name>
<surname><![CDATA[Seeger]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>1989</year>
<volume>7</volume>
<page-range>236-244</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Bernardi]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Conte]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mancini]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Localized respectable neuroblastoma: Results of the second study of the Italian Cooperative Group for Neuroblastoma]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>1995</year>
<volume>13</volume>
<page-range>884-893</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castleberry]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Cantor]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
<name>
<surname><![CDATA[Green]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Phase II investigational window using carboplatin, iproplatin, ifosfamide, and epirubicin in children with untreated disseminated neuroblastoma: A Pediatric Oncology Group study]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>1994</year>
<volume>12</volume>
<page-range>1616-1620</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pinkerton]]></surname>
<given-names><![CDATA[CR]]></given-names>
</name>
<name>
<surname><![CDATA[Zucker]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Hartmann]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Short duration, high dose, alternating chemotherapy in metastatic neuroblastoma: ENSG 3C induction regimen -The European Neuroblastoma Study Group]]></article-title>
<source><![CDATA[Br J Cancer]]></source>
<year>1990</year>
<volume>62</volume>
<page-range>319-323</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Campbell]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Seeger]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Escalating dose of continuous infusion combination chemotherapy for refractory neuroblastoma]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>1993</year>
<volume>11</volume>
<page-range>623-629</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bass]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Watanabe]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Mermel]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Yu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Perner]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Verhaak]]></surname>
<given-names><![CDATA[RG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas]]></article-title>
<source><![CDATA[Nat Genet]]></source>
<year>2009</year>
<volume>41</volume>
<page-range>1238-42</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gangemi]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Griffero]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Marubbi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Perera]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Capra]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Malatesta]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity]]></article-title>
<source><![CDATA[Stem Cells]]></source>
<year>2009</year>
<volume>27</volume>
<page-range>40-8</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodriguez-Pinilla]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Sarrio]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno-Bueno]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Rodriguezil]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Hernandez]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer]]></article-title>
<source><![CDATA[Mod Pathol]]></source>
<year>2007</year>
<volume>20</volume>
<page-range>474-81</page-range></nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Phi]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Paek]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[YJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Sox2 expression in brain tumors: a reflection of the neuroglial differentiation pathway]]></article-title>
<source><![CDATA[Am J Surg Pathol]]></source>
<year>2008</year>
<volume>32</volume>
<page-range>103-12</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Riggi]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Suva]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[De Vito]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Provero]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Stehle]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Baumer]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[EWS-FLI-1 modulates miRNA145 and SOX2 expression to initiate mesenchymal stem cell reprogramming toward Ewing sarcoma cancer stem cells]]></article-title>
<source><![CDATA[Genes Dev]]></source>
<year>2010</year>
<volume>24</volume>
<page-range>916-32</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Zelterman]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Yun]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hypoxia-regulated delta-like 1 homologue enhances cancer cell stemness and tumorigenicity]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>2009</year>
<volume>69</volume>
<page-range>9271-80</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Melone]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Giuliano]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Squillaro]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Alessio]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Casale]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Mattioli]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Genes involved in regulation of stem cell properties: studies on their expression in a small cohort of neuroblastoma patients]]></article-title>
<source><![CDATA[]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B62">
<label>62</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carlsson]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mahlapuu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Forkhead transcription factors: key players in development and metabolism]]></article-title>
<source><![CDATA[Dev Biol]]></source>
<year>2002</year>
<volume>250</volume>
<page-range>1-23</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>63</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kalin]]></surname>
<given-names><![CDATA[TV]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[IC]]></given-names>
</name>
<name>
<surname><![CDATA[Ackerson]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
<name>
<surname><![CDATA[Major]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Detrisac]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kalinichenko]]></surname>
<given-names><![CDATA[VV]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>2006</year>
<volume>66</volume>
<page-range>1712-20</page-range></nlm-citation>
</ref>
<ref id="B64">
<label>64</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dai]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Ban]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lang]]></surname>
<given-names><![CDATA[FF]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Fox- M1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>2006</year>
<volume>66</volume>
<page-range>3593-602</page-range></nlm-citation>
</ref>
<ref id="B65">
<label>65</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Major]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Lepe]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Costa]]></surname>
<given-names><![CDATA[RH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Forkhead box M1B transcriptional activity requires binding of Cdk-cyclin complexes for phosphorylation- dependent recruitment of p300/CBP coactivators]]></article-title>
<source><![CDATA[Mol Cell Biol]]></source>
<year>2004</year>
<volume>24</volume>
<page-range>2649-61</page-range></nlm-citation>
</ref>
<ref id="B66">
<label>66</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Albino]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Scaruffi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Moretti]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Coco]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Truini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Di Cristofano]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Identification of low intratumoral gene expression heterogeneity in neuroblastic tumors by genome-wide expression analysis and game theory]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2008</year>
<volume>113</volume>
<page-range>1412-22</page-range></nlm-citation>
</ref>
<ref id="B67">
<label>67</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Preter]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Vandesompele]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Heimann]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes]]></article-title>
<source><![CDATA[Genome Biol]]></source>
<year>2006</year>
<volume>7</volume>
<page-range>R84</page-range></nlm-citation>
</ref>
<ref id="B68">
<label>68</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lamb]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Crawford]]></surname>
<given-names><![CDATA[ED]]></given-names>
</name>
<name>
<surname><![CDATA[Peck]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease]]></article-title>
<source><![CDATA[Science]]></source>
<year>2006</year>
<volume>313</volume>
<page-range>1929-35</page-range></nlm-citation>
</ref>
<ref id="B69">
<label>69</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
<name>
<surname><![CDATA[Diskin]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Rappaport]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Integrative genomics identifies distinct molecular classes of neuroblastoma and shows that multiple genes are targeted by regional alterations in DNA copy number]]></article-title>
<source><![CDATA[Cancer Res]]></source>
<year>2006</year>
<volume>66</volume>
<page-range>6050-62</page-range></nlm-citation>
</ref>
<ref id="B70">
<label>70</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McArdle]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[McDermott]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Purcell]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Oligonucleotide microarray analysis of gene expression in neuroblastoma displaying loss of chromosome 11q]]></article-title>
<source><![CDATA[Carcinogenesis]]></source>
<year>2004</year>
<volume>25</volume>
<page-range>1599-609</page-range></nlm-citation>
</ref>
<ref id="B71">
<label>71</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gentleman]]></surname>
<given-names><![CDATA[RC]]></given-names>
</name>
<name>
<surname><![CDATA[Carey]]></surname>
<given-names><![CDATA[VJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bates]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Bioconductor: open software development for computational biology and bioinformatics]]></article-title>
<source><![CDATA[Genome Biol]]></source>
<year>2004</year>
<volume>5</volume>
<page-range>R80</page-range></nlm-citation>
</ref>
<ref id="B72">
<label>72</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tusher]]></surname>
<given-names><![CDATA[VG]]></given-names>
</name>
<name>
<surname><![CDATA[Tibshirani]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Chu]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Significance analysis of microarrays applied to the ionizing radiation response]]></article-title>
<source><![CDATA[Proc Natl Acad Sci U S A]]></source>
<year>2001</year>
<volume>98</volume>
<page-range>5116-21</page-range></nlm-citation>
</ref>
<ref id="B73">
<label>73</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Breitling]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Armengaud]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Amtmann]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Herzyk]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments]]></article-title>
<source><![CDATA[FEBS Lett]]></source>
<year>2004</year>
<volume>573</volume>
<page-range>83-92</page-range></nlm-citation>
</ref>
<ref id="B74">
<label>74</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[De Preter]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Barriot]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Speleman]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Vandesompele]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Moreau]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Positional gene enrichment analysis of gene sets for high-resolution identification of overrepresented chromosomal regions]]></article-title>
<source><![CDATA[Nucleic Acids Res]]></source>
<year>2008</year>
<volume>36</volume>
<page-range>e43</page-range></nlm-citation>
</ref>
<ref id="B75">
<label>75</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Subramanian]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Tamayo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Mootha]]></surname>
<given-names><![CDATA[VK]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles]]></article-title>
<source><![CDATA[Proc Natl Acad Sci U S A]]></source>
<year>2005</year>
<volume>102</volume>
<page-range>15545-50</page-range></nlm-citation>
</ref>
<ref id="B76">
<label>76</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Muhlethaler-Mottet]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Meier]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Flahaut]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Complex molecular mechanisms cooperate to mediate histone deacetylase inhibitors anti-tumour activity in neuroblastoma cells]]></article-title>
<source><![CDATA[Mol Cancer]]></source>
<year>2008</year>
<volume>7</volume>
<page-range>55</page-range></nlm-citation>
</ref>
<ref id="B77">
<label>77</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Johnsen]]></surname>
<given-names><![CDATA[JI]]></given-names>
</name>
<name>
<surname><![CDATA[Segerstrom]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Orrego]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Inhibitors of mammalian target of rapamycin downregulate MYCN protein expression and inhibit neuroblastoma growthin vitro and in vivo]]></article-title>
<source><![CDATA[Oncogene]]></source>
<year>2008</year>
<volume>27</volume>
<page-range>2910-22</page-range></nlm-citation>
</ref>
<ref id="B78">
<label>78</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Al Shaer]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Walsby]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gilkes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling]]></article-title>
<source><![CDATA[Br J Haematol]]></source>
<year>2008</year>
<volume>141</volume>
<page-range>483-93</page-range></nlm-citation>
</ref>
<ref id="B79">
<label>79</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ryhanen]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Mannermaa]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Oksala]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Radicicol but not geldanamycin evokes oxidative stress response and efflux protein inhibition in ARPE-19 human retinal pigment epithelial cells]]></article-title>
<source><![CDATA[Eur J Pharmacol]]></source>
<year>2008</year>
<volume>584</volume>
<page-range>229-36</page-range></nlm-citation>
</ref>
<ref id="B80">
<label>80</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lefever]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Vandesompele]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Speleman]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Pattyn]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[RTPrimerDB: the portal for real-time PCR primers and probes]]></article-title>
<source><![CDATA[Nucleic Acids Res]]></source>
<year>2009</year>
<volume>37</volume>
<page-range>D942-5</page-range></nlm-citation>
</ref>
<ref id="B81">
<label>81</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pattyn]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Robbrecht]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[De Paepe]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Speleman]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Vandesompele]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[RTPrimerDB: the real-time PCR primer and probe database, major update 2006]]></article-title>
<source><![CDATA[Nucleic Acids Res]]></source>
<year>2006</year>
<volume>34</volume>
<page-range>D684-8</page-range></nlm-citation>
</ref>
<ref id="B82">
<label>82</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pattyn]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Speleman]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[De Paepe]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Vandesompele]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[RTPrimerDB: the real-time PCR primer and probe database]]></article-title>
<source><![CDATA[Nucleic Acids Res]]></source>
<year>2003</year>
<volume>31</volume>
<page-range>122-3</page-range></nlm-citation>
</ref>
<ref id="B83">
<label>83</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hellemans]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Mortier]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[De Paepe]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Speleman]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Vandesompele]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[qBase relative quantification framework and software for management and automated analysis of real-time quantitative PCR data]]></article-title>
<source><![CDATA[Genome Biol]]></source>
<year>2007</year>
<volume>8</volume>
<page-range>R19</page-range></nlm-citation>
</ref>
<ref id="B84">
<label>84</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vandesompele]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[De Preter]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Pattyn]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes]]></article-title>
<source><![CDATA[Genome Biol]]></source>
<year>2002</year>
<volume>3</volume>
</nlm-citation>
</ref>
<ref id="B85">
<label>85</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mosse]]></surname>
<given-names><![CDATA[YP]]></given-names>
</name>
<name>
<surname><![CDATA[Diskin]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Wasserman]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression]]></article-title>
<source><![CDATA[Genes Chromosomes Cancer]]></source>
<year>2007</year>
<volume>46</volume>
<page-range>936-49</page-range></nlm-citation>
</ref>
<ref id="B86">
<label>86</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tibshirani]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hastie]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Narasimhan]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Chu]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Diagnosis of multiple cancer types by shrunken centroids of gene expression]]></article-title>
<source><![CDATA[Proc Natl Acad Sci U S A]]></source>
<year>2002</year>
<volume>99</volume>
<page-range>6567-72</page-range></nlm-citation>
</ref>
<ref id="B87">
<label>87</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Janoueix-Lerosey]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Novikov]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Monteiro]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Gene expression profiling of 1p35-36 genes in neuroblastoma]]></article-title>
<source><![CDATA[Oncogene]]></source>
<year>2004</year>
<volume>23</volume>
<page-range>5912-22</page-range></nlm-citation>
</ref>
<ref id="B88">
<label>88</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lastowska]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Viprey]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Santibanez-Koref]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data]]></article-title>
<source><![CDATA[Oncogene]]></source>
<year>2007</year>
<volume>26</volume>
<page-range>7432-44</page-range></nlm-citation>
</ref>
<ref id="B89">
<label>89</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Falini]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Mecucci]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Tiacci]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2005</year>
<volume>352</volume>
<page-range>254-66</page-range></nlm-citation>
</ref>
<ref id="B90">
<label>90</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Minucci]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pelicci]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer]]></article-title>
<source><![CDATA[Nat Rev Cancer]]></source>
<year>2006</year>
<volume>6</volume>
<page-range>38-51</page-range></nlm-citation>
</ref>
<ref id="B91">
<label>91</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tang]]></surname>
<given-names><![CDATA[XX]]></given-names>
</name>
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Riceberg]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Favorable neuroblastoma genes and molecular therapeutics of neuroblastoma]]></article-title>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2004</year>
<volume>10</volume>
<page-range>5837-44</page-range></nlm-citation>
</ref>
<ref id="B92">
<label>92</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hahn]]></surname>
<given-names><![CDATA[CK]]></given-names>
</name>
<name>
<surname><![CDATA[Ross]]></surname>
<given-names><![CDATA[KN]]></given-names>
</name>
<name>
<surname><![CDATA[Warrington]]></surname>
<given-names><![CDATA[IM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Expression-based screening identifies the combination of histone deacetylase inhibitors and retinoids for neuroblastoma differentiation]]></article-title>
<source><![CDATA[Proc Natl Acad Sci U S A]]></source>
<year>2008</year>
<volume>105</volume>
<page-range>9751-6</page-range></nlm-citation>
</ref>
<ref id="B93">
<label>93</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kamal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Burrows]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
<name>
<surname><![CDATA[Evers]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
<name>
<surname><![CDATA[Chung]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Inhibition of neuroblastoma xenograft growth by Hsp90 inhibitors]]></article-title>
<source><![CDATA[Anticancer Res]]></source>
<year>2006</year>
<volume>26</volume>
<page-range>1903-8</page-range></nlm-citation>
</ref>
<ref id="B94">
<label>94</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bagatell]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Beliakoff]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[David]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Marron]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
<name>
<surname><![CDATA[Whitesell]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2005</year>
<volume>113</volume>
<page-range>179-88</page-range></nlm-citation>
</ref>
<ref id="B95">
<label>95</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bagatell]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Gore]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Egorin]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study]]></article-title>
<source><![CDATA[Clin Cancer Res]]></source>
<year>2007</year>
<volume>13</volume>
<page-range>1783-8</page-range></nlm-citation>
</ref>
<ref id="B96">
<label>96</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sharma]]></surname>
<given-names><![CDATA[SV]]></given-names>
</name>
<name>
<surname><![CDATA[Agatsuma]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Nakano]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Targeting of the protein chaperone, HSP90, by the transformation suppressing agent, radicicol]]></article-title>
<source><![CDATA[Oncogene]]></source>
<year>1998</year>
<volume>16</volume>
<page-range>2639-45</page-range></nlm-citation>
</ref>
<ref id="B97">
<label>97</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Misawa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Hosoi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Tsuchiya]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Sugimoto]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2003</year>
<volume>104</volume>
<page-range>233-7</page-range></nlm-citation>
</ref>
<ref id="B98">
<label>98</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gil-Ad]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Shtaif]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Levkovitz]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Dayag]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zeldich]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Weizman]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Characterization of phenothiazine-induced apoptosis in neuroblastoma and glioma cell lines: clinical relevance and possible application for brain-derived tumors]]></article-title>
<source><![CDATA[J Mol Neurosci]]></source>
<year>2004</year>
<volume>22</volume>
<page-range>189-98</page-range></nlm-citation>
</ref>
<ref id="B99">
<label>99</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Shamji]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Matchacheep]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Schreiber]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Identification of a small-molecule inhibitor of class Ia PI3Ks with cell-based screening]]></article-title>
<source><![CDATA[Chem Biol]]></source>
<year>2007</year>
<volume>14</volume>
<page-range>371-7</page-range></nlm-citation>
</ref>
<ref id="B100">
<label>100</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Marone]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Cmiljanovic]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Giese]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Wymann]]></surname>
<given-names><![CDATA[MP]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Targeting phosphoinositide 3-kinase: moving towards therapy]]></article-title>
<source><![CDATA[Biochim Biophys Acta]]></source>
<year>2008</year>
<volume>1784</volume>
<page-range>159-85</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
